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One strategy being evaluated for HIV-1 vaccine development is focusing immune responses towards
neutralizing epitopes on the gp120 outer domain (OD) by removing the immunodominant, but non-
neutralizing, inner domain. Previous OD constructs have not elicited strong neutralizing antibodies
(nAbs). We constructed two immunogens, a monomeric gp120-OD and a trimeric gp120-OD3, based
on an M group consensus sequence (MCON6). Their biochemical and immunological properties were
compared with intact gp120. Results indicated better preservation of critical neutralizing epitopes on
gp120-OD3. In contrast to previous studies, our immunogens induced potent, cross-reactive nAbs in
rabbits. Although nAbs primarily targeted Tier 1 viruses, they exhibited signiﬁcant breadth. Epitope
mapping analyses indicated that nAbs primarily targeted conserved V3 loop elements. Although the
potency and breadth of nAbs were similar for all three immunogens, nAb induction kinetics indicated
that gp120-OD3 was superior to gp120-OD, suggesting that gp120-OD3 is a promising prototype for
further gp120 OD-based immunogen development.
& 2014 Elsevier Inc. All rights reserved.
Introduction
According to the 2013 UNAIDS report on the global Acquired
Immunodeﬁciency Syndrome (AIDS) epidemic, an estimated 35.3
million people were infected with human immunodeﬁciency virus
type 1 (HIV-1) in 2012. Despite the existence of highly effective
anti-viral drugs, there were still 2.3 million new HIV-1 infections
in 2012. A vaccine that could elicit broadly neutralizing antibodies
(bnAbs) is hypothesized to be the most effective means to stop the
AIDS pandemic (Haynes and Monteﬁori, 2006; Hoxie, 2010;
Mascola and Monteﬁori, 2010). Unfortunately, eliciting bnAbs
against HIV-1 has been a major scientiﬁc challenge (Ross et al.,
2010). Several factors contribute to this difﬁculty, including the
high mutation rate, extensive glycosylation (Wyatt et al., 1998),
and signiﬁcant conformational ﬂexibility of the envelope glyco-
protein (Karlsson Hedestam et al., 2008; Kwong et al., 2011), as
well as low envelope spike density on the virion surface (Klein and
Bjorkman, 2010; Klein et al., 2009).
The HIV-1 envelope glycoprotein is the sole known target of
nAbs against the virus. It is comprised of two subunits; a sur-
face glycoprotein, gp120, that contains the receptor (CD4) and co-
receptor (viz. CCR5 or CXCR4) binding sites; and a transmembrane
glycoprotein, gp41, that mediates fusion between the viral and the
host cellular membranes (reviewed in LaBranche et al., 2001;
Pantophlet and Burton, 2006; Wyatt and Sodroski, 1998). These
two subunits form a trimeric heterodimer (Center et al., 2002,
2001; Zhu et al., 2003). Structurally, gp120 is divided into three
domains: an inner domain (ID), an outer domain (OD), and a
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bridging sheet that connects the two (Kwong et al., 1998). In the
native trimeric envelope spike, the ID is buried internally
while the OD is exposed on the surface (Kwong et al., 2000).
The envelope glycoprotein has four conserved regions that are
targeted by potent bnAbs isolated from HIV-1 infected patients:
(1) the CD4 binding site (e.g. b12, VRC01, NIH45-46, 3BNC117
(Burton et al., 1991; Diskin et al., 2011; Scheid et al., 2011;. Wu
et al., 2010)), (2) glycans around N160 along with conserved
elements on V1/V2 (e.g. PG9, PG16 (Walker et al., 2009)), (3) gly-
cans and the base of V3 loop around N332 (e.g. 2G12 and PGT
antibodies, including PGT128 (Buchacher et al., 1994; Walker et al.,
2011)), and (4) the membrane-proximal external region (MPER) of
gp41 (e.g. 2F5, Z13e1, 4E10 and 10E8 (Huang et al., 2012; Muster
et al., 1994; Purtscher et al., 1994; Stiegler et al., 2001; Zwick et al.,
2001; also reviewed in Kwong and Mascola, 2012; Kwong et al.,
2013). A number of bnAbs that target other novel epitopes have
also been isolated more recently: 3BC176 and 3BC315 that target a
region near the V3 loop and the CD4i site (Klein et al., 2012),
8ANC195 that recognizes portions of gp41 and N-linked glycans
adjacent to the CD4BS (Scharf et al., 2014), and PGT151 that targets
a glycan-dependent epitope at the interface of gp120 and gp41
(Blattner et al., 2014; Falkowska et al., 2014).
Considering that many of the epitopes targeted by bnAbs are on
the gp120 OD and that the highly immunodominant ID elicits non-
neutralizing antibodies, it has been hypothesized that immuno-
gens comprised of only the OD are better able to induce bnAbs
than the intact gp120 (Kwong et al., 2011; Nabel et al., 2011; Zhou
et al., 2007). Unfortunately, previous immunization studies using
OD-based immunogens have largely been unsuccessful. Yang et al.
(2004) expressed a clade B YU2 OD construct, termed OD1. The
OD1 protein could be recognized by 2G12 and various anti-V3
human mAbs, but not by b12. In a later study, however, it was
shown by surface plasmon resonance (SPR) that b12 could bind
OD1, but with a high dissociation rate (Zhou et al., 2007). The
protein also failed to bind CD4. Not surprisingly, rabbits immu-
nized with OD1 failed to mount detectable levels of nAbs against
HIV-1KB9 or HIV-1YU2.
In another study, Chen et al. (2007, 2008) immunized mice
with a clade C virus OD (CN54) fused to the human IgG1 Fc domain
as an immune enhancer. However, there were no neutralizing
activities in the mice sera. Bhattacharyya et al. (2010) designed an
OD-based immunogen (ODEC) from HIV-1 HxBc2. The ODEC protein
was expressed in Escherichia coli and, therefore, it was not
glycosylated. It also lacked the variable loops V1/V2 and V3, and
11 mutations were introduced to increase binding afﬁnity to CD4
and IgG1 b12. However, the sera from immunized rabbits showed
only marginal neutralizing activity against four clade B viruses and
one clade C virus. Wu et al. (2009) generated a membrane-
anchored OD containing residues 252–482 from the HIV-1 clade
B virus TAI-R3A. This OD variant had a truncated β20-β21 hairpin
and a shortened V3 loop, fused to the transmembrane region of
CD4. This optimized, membrane-anchored OD could be recognized
by b12 and b13, but was not recognized by other CD4 binding site
(CD4BS) antibodies. Joyce et al. (2013) recently reported an
antigenically optimized OD4.2.2 from the clade A KER2018 strain,
which could bind to VRC01 with nanomolar afﬁnity. However, its
immunogenic properties were not reported.
Despite these unsuccessful attempts to induce bnAbs using
immunogens based on gp120 OD, it is our hypothesis that focusing
immune responses to the OD of gp120 is still worth pursuing
based on one or more of the following reasons: (1) the immuno-
gens tested thus far have not been tested rigorously for their
proper antigenic conformation, (2) the immunogens were based
on a single HIV-1 isolate, and (3) the adjuvants used in these
studies may not have been ideal to maintain correct antigenic
structures. In this report, we describe our attempt to design and
evaluate gp120 OD-based immunogens to induce bnAbs in rabbits.
The results suggest that our immunogens and/or the antigen
delivery system we used are better than others reported thus far
in inducing nAbs against HIV-1.
Results
Construction, expression and puriﬁcation of monomeric and trimeric
forms of gp120 OD, and gp120
In past studies of generating immunogens based on gp120 OD,
envelope protein sequences from a single HIV-1 isolate from a
given clade were used. Considering that centralized HIV-1 anti-
gens based on ancestral, consensus or a phylogenetic tree center
sequences have been suggested to have the potential to increase
the breadth of immune responses (Gao et al., 2004; Gaschen et al.,
2002; Nickle, 2003), we have chosen to use an M group consensus
sequence for generating our immunogens (MCON6, (Gao et al.,
2005)). Antisera from guinea pigs immunized with recombinant
MCON6 gp120 have previously been shown to neutralize several
HIV-1 primary isolates, albeit weakly and somewhat sporadically
(Gao et al., 2005).
First, we generated gp120-OD by cloning 249STQLLL…RPGGGD477
(numbering based on MCON6) fused to the signal peptide (Fig. 1A). In
addition to monomeric gp120-OD, we also constructed a trimeric
form (gp120-OD3), which contains three tandem copies of OD
covalently linked by a four amino acid linker (RVTG). The rationale
for generating OD3 was as follows: when the ID is removed from
gp120, the interface between the two domains would be exposed
(Fig. 1B). The newly exposed surface could potentially be immuno-
genic, which might decrease immunogenicity of critical neutralizing
epitopes on the OD. Because the N-terminal and the C-terminal ends
of gp120-OD (S249 and D477, respectively) are on the same face of the
protein and in close proximity, we hypothesized that it might be
possible to “mask” the newly exposed surface from the immune
system by bringing the three tandem copies close together by
covalently linking them with a short, four amino acid linker. One
potential beneﬁt of trimerizing gp120-OD was enhancement of
immunogenicity by increasing the valency of epitopes. In addition
to gp120-OD and gp120-OD3, we constructed the intact gp120 for
comparing immunogenicity.
All three proteins were expressed efﬁciently in HEK293 cells,
and all of them could be puriﬁed to near homogeneity using a
combination of afﬁnity chromatography (Con A and Ni-NTA) and
ion-exchange chromatography using Q-sepharose (Fig. 1C).
Approximate molecular weights of gp120, gp120-OD, and
gp120-OD3 were 120 kD, 60 kD and 180 kD, respectively.
Gp120-OD migrated as a broad smear, suggesting signiﬁcant
heterogeneity in glycosylation. Deglycosylation analyses with
EndoH and PNGaseF showed that proteins are glycosylated with
both high-mannose and complex carbohydrates (Fig. 1D). Fully
deglycosylated gp120-OD, gp120-OD3 and gp120 migrated as
expected theoretical molecular weights of 26 kD, 75 kD and 55
kD, respectively.
Antigenic properties of gp120, gp120-OD and gp120-OD 3
To evaluate whether OD-based immunogens were conforma-
tionally intact, their antigenic properties were examined by
immunoprecipitation using multiple nAbs and compared to that
of gp120. First, the prototypic nAbs that target a variety of epitopes
were tested: 17b (bridging sheet), b12 (CD4BS), 2G12 (carbohy-
drate) and 447-52D (V3 loop). As shown in Fig. 2A, gp120 was
immunoprecipitated by all four nAbs. Among the four antibodies
tested, b12 appeared the most efﬁcient. Both gp120-OD
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and -OD3 also could be immunoprecipitated by all nAbs except
17b (Fig. 2B and C); this was expected since two of the four
β-strands that make up the bridging sheet were removed along
with the ID. Despite reactivity of gp120-OD and -OD3 to b12, it
was weaker relative to other nAbs when compared to gp120. It
should also be noted that both of these proteins failed to bind
soluble CD4, as tested by co-immunoprecipation, and that they did
not bind to b12 antibody when tested by ELISA (data not shown),
suggesting that structural elements on or near the CD4BS are
unstable, ﬂexible or prone to misfolding (e.g. when bound to ELISA
plate). Compared to gp120 and gp120-OD, the degree of immu-
noreactivity of gp120-OD3 to 2G12 and 447-52D was remark-
able. This is likely due to the fact that OD3 has three copies of
the epitopes, which should enhance antigen–antibody complex
formation.
To better characterize kinetic parameters of interaction between
b12 and three proteins, surface plasmon resonance (SPR) analyses
were conducted. As shown in Fig. 2D and Table 1, the association
constant (Ka) between b12 and gp120-OD was about 2-fold higher
than that for gp120, suggesting that b12 was able to bind to gp120-
OD faster. However, the dissociation constant (Kd) between b12 and
gp120-OD was greater than 20-fold higher compared to that for
gp120, indicating signiﬁcantly lower afﬁnity between b12 and
gp120-OD. A similar result was reported by Zhou et al. (2007). All
together, the equilibrium dissociation constant (KD) was about 10
fold lower for gp120 than gp120-OD. The kinetic parameters for
gp120-OD3 were similar to those of gp120, indicating improved
antigenic proﬁle of gp120-OD3 compared to the monomeric
gp120-OD.
More recently, bnAbs against HIV-1 with excellent potency and
breadth have been isolated from virus-infected patients (Diskin et
al., 2011; Scheid et al., 2011; Walker et al., 2009; Wu et al., 2010).
To further characterize antigenic properties of the three proteins,
they were probed with bnAbs that target the CD4BS (VRC01,
3BNC60, NIH45-46), and those that bind to glycans around N160
along with conserved elements on V1/V2 (PG9 and PG16). The
intact gp120 bound to all bnAbs, except for PG16 (Fig. 2E).
Although CD4BS bnAbs could recognize both gp120-OD and
-OD3, the reactivity seemed to be lower (Fig. 2F and G). As
expected, they did not bind to PG9 or PG16. SPR analyses were not
conducted due to limited availability of these antibodies. Alto-
gether, the results from these studies showed that antigenic
Fig. 1. Schematic diagram, expression and puriﬁcation of gp120, gp120-OD and -OD3. (A) A schematic diagram of three immunogens. All proteins contain N-terminal
signal peptide (SP) and C-terminal 6His tag. For gp120-OD3, the OD segments are connected by a four amino acid linker (RVTG). (B) Structural representations of gp120
and gp120-OD. The OD and ID are shown in green and ice blue, respectively. The V3 loop is shown in orange. The N- and C-terminal ends of gp120-OD (S249 and D477,
respectively), as well as the interface region between ID and OD are indicated. The crystal structure of trimeric gp140 SOSIP (4NCO) was used (Khayat et al., 2013). (C) Silver
stain of puriﬁed proteins expressed in HEK293 cells. (D) Western Blot analyses of deglycosylated proteins. Lane 1: untreated; lane 2: EndoH; lane 3: PNGaseF.
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structures of epitopes targeted by bnAbs appear better preserved
in our gp120-OD and -OD3 than other OD-based antigens
described in past immunogenicity studies.
Antibody responses against gp120, gp120-OD and gp120-OD3
in rabbits
Many of the epitopes targeted by bnAbs that bind gp120 are
non-linear and/or highly conformational. Thus, using adjuvants
that can preserve the correct antigenic structure would be critical,
especially for proteins like our gp120-OD and gp120-OD3 that
may be more prone to denaturation. Accordingly, we have chosen
to use Zn-chitosan as an antigen delivery platform/adjuvant,
instead of using adjuvants that contain oil or agents that exhibit
chaotropic properties that could potentially disrupt the epitope
structure. Chitosan is a cationic polysaccharide (repeating units
Fig. 2. Evaluation of antigenic properties. Immunoprecipitation analyses of gp120 (A), gp120-OD (B) and gp120-OD3 (C) with mAbs 17b, b12, 2G12 and 447-52D. SPR
analyses of interactions between IgG b12 and gp120, gp120-OD and -OD3. Immunoprecipitation analyses of gp120 (E), gp120-OD (F) and gp120-OD3 (G) with more
recently isolated bnAbs VRC01, 3BNC60, NIH45-46, PG9 and PG16.
Table 1
Kinetic parameters for IgG1 b12 interaction with gp120, gp120-OD and gp120-
OD3.
Protein Ka(1/Ms) Kd(1/S) KD¼(Kd/Ka)
gp120 3.64104 1.83103 5.02108
gp120-OD 8.05104 4.18102 5.19107
gp120-OD3 4.08104 1.98103 4.85108
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of β-(1–4)-linked D-glucosamine and N-acetyl-D-glucosamine),
derived by the partial deacetylation of chitin. It is nontoxic, bio-
compatible and biodegradable, and has been used effectively as an
adjuvant (Marcinkiewicz et al., 1991; Seferian and Martinez, 2000;
Singla and Chawla, 2001; van der Lubben et al., 2001). One
property of chitosan is that it can be generated as a metal ion
complex with zinc (Zn). Zn-chitosan has a property similar to that
of Ni-NTA such that proteins with 6His residues can be bound
(Seferian and Martinez, 2000). Thus, Zn-chitosan could also func-
tion as an antigen depot that allows slow release of antigens for
extended stimulation of the immune system.
Three rabbits were immunized subcutaneously with each
antigen on weeks 0, 3, 9, 15 and 27. Two control animals were
inoculated with Zn-chitosan only in PBS. Serum samples were
collected before (preimmune) and two weeks after each immuni-
zation. Antibody responses were monitored by ELISA using auto-
logous antigens and the end-point antibody titers against each
immunogen are shown in Fig. 3. All three protein constructs were
highly immunogenic; high end-point titers of antibodies were
induced even after a single immunization: 4.7105 (gp120-OD),
4.8105 (gp120-OD3) and 8.5104 (gp120). Although there
were a few minor differences, the antibody induction kinetics
were fairly similar for the three proteins. Generally, antibody
titers reached the maximal levels after the second immunization,
although it continued to increase slightly in gp120-OD-immunized
animals. The end-point titers after the ﬁnal immunization
were 3.1107 (gp120-OD), 1.9107 (gp120-OD3) and 1.0
107 (gp120).
Identiﬁcation of immunogenic linear epitopes within the OD
In order to better characterize antibody responses and to
compare immunogenic properties of gp120, gp120-OD and
-OD3, we identiﬁed immunogenic linear epitopes in the OD
region by conducting ELISA with overlapping peptides using
immune sera collected after the ﬁfth immunization (Fig. 4). For
this analysis, we used peptides available from NIH AIDS RRRP
which are based on M group consensus sequence designated as
MCONS. Although there are some differences in amino acid
sequences between MCONS and MCON6 we used to generate
our immunogens, the variant residues are mostly in the variable
loops. Due to the high density of variant residues in the V4 and V5
loops, separate MCON6 peptides were used for these loops.
Although there were some differences among the three
immunogens and animal-to-animal variations within the group,
most of the immunoreactive peptides were within the V3, C4 and
V5 regions (Fig. 4A).
Overall, the V3 loop was most immunogenic. The N-terminal
half of the loop (peptides 9047-CTRPNNNTRKSIRIG, 9048-NNN-
TRKSIRIGPGQA and 9049-rksirigpgqafyat) was more immunogenic
than the C-terminal half (peptides 9051-GQAFYATGDIIGDIR, 9052-
YATEDIIGDIRQAHC and 9053-DIIGDIRQAHCNISG) (Po0.0001 for
gp120 and gp120-OD; P¼0.0039 for gp120-OD3). This was
more evident after the fourth immunization (Fig. 4B). A similar
result was observed in a previous study that evaluated immuno-
genicity of JR-FL gp120 in rabbits (Vaine et al., 2008). The central
core of the epitopes recognized in the N-terminal peptides
appeared to be “RKSIRIG”, designated as V3-N (Fig. 4C). Interest-
ingly, the C-terminal half of the V3 loop was more immunogenic in
the context of gp120-OD3 than in gp120 (Po0.0001) or gp120-
OD (P¼0.0028), especially for peptides 9052 and 9053; antibodies
were observed consistently in all of the immunized animals even
after the fourth immunization. Strong reactivity of these two
peptides suggests DIIGDIRQAHC as the core of the epitope being
recognized (designated as V3-C; Fig. 4C). These results may
suggest some subtle differences in the structure or accessibility
of this epitope between gp120-OD3 and the other two immu-
nogens. Antibodies that recognized upstream of this core were
also observed after the ﬁfth immunization (peptides 9050
and 9051).
Three peptides in the C4 region (9078-MWQGVGQAMYAPPIE,
9079-vgqamyappiegkit and 9080-MYAPPIEGKITCKSN) were highly
reactive to antibodies induced in gp120-OD and -OD3-immu-
nized rabbits. No anti-C4 antibodies were induced in gp120-
immunized animals after the fourth immunization (Fig. 4B) and
modest levels of antibodies against only peptides 9079 and 9080
were observed after the ﬁfth immunization, indicating these
epitopes are signiﬁcantly less immunogenic in the intact gp120
(Po0.0001 compared to either gp120-OD or -OD3). This is not
surprising since the likely core of the epitope “MYAPPIE” lies in the
interface between OD and ID of gp120 and becomes exposed only
when the ID is removed (Fig. 4C).
Peptides (MCONS) covering the V5 region were reactive to
antisera only weakly or sporadically. One possible reason was
difference in amino acid sequence between MCONS-based pep-
tides and MCON6-based immunogens used to immunize rabbits
since there are four amino acids different within a stretch of
eight amino acids in the V5 region (see top of Fig. 4A). Indeed,
when ELISA was performed using a peptide based on MCON6
sequence (GNNSNKNKTETFRPG; underline represents variant resi-
dues between MCON6 and MCONS) a strong antibody response
was observed for all three immunogens (Fig 4A, right panel). This,
however, was not the case for the V4 loop, indicating that V4 loop
is not immunogenic in the context of all three immunogens we
tested. Alternatively, the peptide we used is unable to mimic the
structure that exists in the whole protein.
Although immunogenic epitopes on the intact gp120 were also
found to be immunogenic in gp120-OD and -OD3, there were a
few subtle differences, especially for gp120-OD. There were multi-
ple peptides that reacted to antisera against gp120-OD, but not at
all or less to gp120 or gp120-OD3. They included peptides
9043–9046 in C2 just upstream of the V3 loop (Po0.0001 for
gp120-OD vs. gp120 or gp120-OD3) and peptides 9063–9066 in
C3 (Po0.0001 for gp120-OD vs. -OD3; P¼0.0085 for gp120-OD
vs. gp120). These results could be simply due to greater exposure
of epitopes that were masked on gp120 or masking of epitopes as
a result of trimerization on gp120-OD3. Interestingly, these two
regions are in close proximity to amino acid residues that make up
contact residues to CD4 and/or VRC01 (i.e. Loop D and CD4 binding
loop; see blue circles under gp120 ELISA data).
Fig. 3. Antibody endpoint titers determined by ELISA. Sera obtained before or
2 weeks after each immunization were monitored for autologous antigen-speciﬁc
antibodies by ELISA. Data are presented as average endpoint titers of three rabbits
with standard deviation (SD).
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Induction of nAbs by gp120, gp120-OD and gp120-OD 3
Next, we compared neutralizing activity of antibodies induced by
the three immunogens. For the initial analyses, a panel of eight
viruses including seven Tier 1 viruses and one Tier 2 virus was tested
(Table 2). Antisera collected after the ﬁfth immunization were used.
All three immunogens induced nAbs against Tier 1, clade B (MN.3,
SF162.LS, W61D-TCLA.71, Bal.26), clade C (MW965.26) and clade AE
(TH023.6) pseudoviruses, but not Clade A (Q23.17). Of these six
viruses, Bal.26 was least neutralization sensitive. None of the
preimmune antisera exhibited neutralizing activity (data not shown).
One each of the rabbits immunized with gp120 or gp120-OD3
showed weak neutralizing activity against Tier 2, clade B isolate
(6535.3). Unfortunately, no neutralizing activity was observed
against other Tier 2 viruses tested (clade B, PVO.4 and SC422661.8).
Analysis of aggregated ID50s from TZM-bl assays showed a general
trend of gp1204gp120-OD34gp120-OD (Fig. 5A). However, the
differences were not statistically signiﬁcant. Although neutralizing
activity was largely limited to Tier 1 viruses, these results are
important considering that (1) the activity was induced by a
synthetic sequence against heterologous virus isolates, (2) neutraliz-
ing activity was observed against virus isolates from different clades,
and (3) all three immunogens induced fairly potent nAbs, including
OD-based immunogens, which have not been successful in other
previously reported studies.
Neutralizing activities of the immune sera against Tier 2 viruses
(clade B: CH58, THRO and WITO; clade C: Ce1086_B2, DU151.2,
Ce1176_A3, Ce2010_F5, and Du422.1) were further analyzed by a
more sensitive assay using A3R5.7 cells (41, 42). Analysis showed that
neutralizing activity against Tier 2 viruses could be detected in
Fig. 4. Comparison of immunogenic linear epitopes by ELISA using overlapping peptides. (A) ELISA using immune sera after the ﬁfth immunization. Peptide numbers
represent catalog numbers from the NIH AIDS RRRP. On the top of the ﬁgure shows a schematic diagram of gp120-OD, MCONS envelope sequence, identiﬁcation of amino
acid residues different from MCON6 (small red square), and sequence of MCON6 peptides covering the V4 and V5 region (red text). Blue circles below gp120 ELISA data
indicates amino acid residues that makes contact with CD4 and/or VRC01. (B) ELISA of select peptides from the V3 and C4 regions with immune sera after the fourth
immunization. (C) Plotting of four immunogenic epitopes onto a crystal structure of trimeric gp140 SOSIP (4NCO). Two segments within V3 loop (red and blue), one in C4
(magenta) and one in V5 (gold). Only the likely cores of the V3 and C4 epitopes (boxed in) are plotted on the crystal structure.
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immune sera against all three proteins; however they were
relatively weak and sporadic (Fig. 5B). Interestingly, gp120 induced
signiﬁcantly better nAbs against Tier 2 viruses than both gp120-OD
and -OD3 (p¼0.0086 and 0.0044, respectively). Results were not
statistically different between gp120-OD and -OD3 (p¼0.5955).
Considering there were some differences in antigenic and
immunogenic properties, especially for gp120-OD, we next exam-
ined whether there might be any differences in the kinetics of nAb
induction among the three immunogens. For these analyses,
neutralizing activities of immune sera collected after each immu-
nization were evaluated against Tier 1, clade B SF162.LS (Fig. 6A)
and clade C MW965.26 (Fig. 6B). As shown in Fig. 6A, neutralizing
activities were detected in all three groups after the second
immunization; no neutralizing activities were observed after the
ﬁrst immunization or in mock-immunized animals (data not
shown). The activity was signiﬁcantly lower for gp120-OD group
compared to gp120 and gp120-OD3 (over 12- and 11-fold,
respectively). However, the nAb titers for the gp120-OD group
increased successively with each immunization. In contrast, the
nAb titers for the gp120-OD3 group reached near plateau after
the second immunization and did not increase signiﬁcantly after
additional immunizations. The nAb titers for the gp120 group also
seemed to have reached maximum after the second immunization.
Unexpectedly, the titer actually decreased after the third and the
fourth immunization. The titer increased after the ﬁfth immuniza-
tion, but only to the level achieved after the second immunization.
Together, these results suggest that gp120-OD3 is superior to
gp120-OD and also perhaps to gp120 in that it requires fewer
immunizations and is better able to sustain higher nAb titers. The
overall pattern of neutralizing activity against MW965.26 was
similar although the differences between the groups were less
obvious (Fig. 6B).
Neutralizing activity of puriﬁed IgG
To conﬁrm neutralizing activities are indeed conferred by
antibodies, IgG was puriﬁed from immune sera of all immunized
rabbits and evaluated against Tier 1 clade B (SF162.LS) and clade C
(MW965.26) viruses. As shown in Fig. 7, puriﬁed IgG exhibited
potent neutralizing activity against both viruses. ID50 of serum
neutralization inversely correlated with IC50 of IgG concentration,
conﬁrming that IgG is responsible for the neutralizing activity. For
Table 2
Neutralizing antibody titers of rabbit antisera after 5th immunization in TZMbl.
a Values are the serum dilution at which relative luminescence units (RLUs) were reduced 50% compared to virus control wells (no sera sample). Sera from rabbits after
the ﬁfth immunization with each antigen were tested against the indicated pseudoviruses. All sera failed to neutralize murine leukemia virus pseudovirus at the lowest
serum dilution tested (1:20) (data not shown). NT, not tested. Color scale: red, ID50410,000; orange, 5000 to 9999; yellow, 1,000–4,999; green 100 to 999; blue, 20 to 99;
white,o20.
Fig. 5. Aggregate analyses of ID50 values of neutralizing activity. (A) Data from neutralization assay using TZM-bl cells. Data shown in Table 2 are presented.
(B) Neutralization assay against Tier 2 pseudoviruses using A3R5 cells. Neutralization assays were done using immune sera collected after the ﬁfth immunization. Mean
with standard error is shown.
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example, the ID50s for gp120-OD3 rabbits 2 and 3 against
MW965.26 were 169 and 9499, respectively. IC50s of puriﬁed IgG
from the corresponding samples were 16.1 and 1.1 mg/ml, respec-
tively. IgG puriﬁed from one of the two mock-immunized animals
(PBS-2) exhibited no neutralizing activity.
Deﬁning neutralization epitope(s)
Since the V3 loop was highly immunogenic for all three
immunogens (Fig. 4), it seemed likely that the V3 loop could be
a major neutralizing epitope. To conﬁrm this, we conducted a
neutralization inhibition assay using the MCON6 V3 loop peptide
(TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH). For this analysis,
neutralizing activity of puriﬁed IgG (50 mg/ml) from one rabbit
from each immunogen group that exhibited the highest neut-
ralizing activity was evaluated (i.e. gp120-OD-1, -OD3-3, and
gp120-2) in the presence or the absence of various concentrations
of the peptide. The IC50 values of these IgG samples were fairly
comparable (1.9, 0.6, and 0.9 mg/ml against SF162.LS, and 2.3, 1.1,
and 1.6 mg/ml against MW965.26, respectively). VRC01 (5 mg/ml)
was used as a negative control. As shown in Fig. 8, neutralization
of both SF162.LS and MW965.26 viruses by gp120-OD-induced
nAbs was efﬁciently inhibited by the peptide. In contrast, neu-
tralizing activity of VRC01 was not affected, as expected. Neutra-
lization of both viruses by gp120-OD3-induced nAbs was also
inhibited, but higher concentrations of the peptide were required.
This could be simply due to higher anti-V3 loop antibody response
induced by gp120-OD3. Neutralization of SF162.LS by gp120-
induced nAbs was also similarly inhibited. Interestingly, however,
inhibition of neutralizing activity against MW965.26 was less
efﬁcient, reaching maximal inhibition of only about 40%. One
plausible explanation is that this could be due to the presence of
nAbs that targets epitopes outside of the V3 loop. In fact,
neutralizing activity also could not be completely inhibited when
using the entire gp120-OD protein as an inhibitor (data not
shown), indicating that neutralizing epitope(s) could lie within
the ID (e.g. V1/V2 loops), or requires structural elements of both
the inner and the outer domains. Not surprisingly, immunoreac-
tive C4 peptides (peptides #9078, 9079 and 9080) did not inhibit
neutralizing activity (data not shown).
Discussion
In this report, we described construction, expression and
puriﬁcation of three different immunogens (gp120, gp120-OD
and -OD3) based on an M group consensus sequence (MCON6).
We evaluated their antigenic properties using variety of nAbs and
assessed their potential to induce nAbs in rabbits. All three
immunogens induced potent nAbs that were able to neutralize
viruses from three different clades including clade B (MN, SF162.
LS, W61D-TCLA.71 and Bal.26), clade C (MW965.26), and clade AE
(TH023.6). Although neutralizing activity was limited largely to
Tier 1 viruses, results are still meaningful considering that pre-
vious OD-based immunogens reported by other investigators have
either failed to induce or induced nAbs with lessor breadth and/or
modest potency (Bhattacharyya et al., 2010; Chen et al., 2007;
Yang et al., 2004).
One possible reason why we were able to induce potent nAbs
with our OD-based constructs when others failed to do so is that
we used an antigen-delivery platform/adjuvant that may have
been better at preserving the native structure of the proteins, yet
had potent immunostimulating properties. In the study conducted
by Yang et al. (2004), rabbits were immunized with their OD1
construct using 1Ribi as an adjuvant, which is an oil-in-water
emulsion. Considering that OD-based proteins might already be
structurally unstable with many hydrophobic amino acid residues
exposed on the surface (on the interface between the inner and
the outer domains), exposure to oil likely denatured the protein.
Similarly, Bhattacharyya et al. (2010) used Freund's adjuvant,
which is a water-in-oil emulsion. Chen et al. (2007) used an OD
construct fused with the human IgG1 Fc domain to function as an
adjuvant. Immunization of mice yielded end-point antibody titers
of only about 400, and no neutralizing activity was detected. Low
antibody titer suggests ineffectiveness of IgG1 Fc as an adjuvant.
In our study we used Zn-chitosan, which is a cationic poly-
saccharide chelated with Zn. Our immunogens could be loaded
onto the matrix simply by gently mixing the two components in a
near-physiological buffer (PBS, pH 8.0). As such, our methodology
likely preserved the native antigenic conformation of potential
neutralizing epitopes on gp120. Yet, chitosan exhibited high
immunostimulatory properties, inducing 105–106 end-point
Fig. 6. Kinetic analyses of neutralizing antibodies induced by gp120, gp120-OD, and -OD3. (A) Neutralizing activity against clade B SF162.LS with immune sera collected
after the second, third, fourth, and ﬁfth immunization. The geometric mean titer for each group of sera is shown as a horizontal bar. Statistical analysis was done with Prism
GraphPad 5 using a two-tailed t-test. **Po0.01; *0.01oPo0.05. (B) Neutralizing activity against clade C MW965.26. There were no statistical differences between the
groups.
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antibody titers after the ﬁrst immunization and 106–107 after the
second immunization.
Another possible reason why we were able to induce fairly
potent nAbs with our immunogens is the immunogens themselves
(e.g. cellular origins of recombinant proteins, primary amino acid
sequences, extent of glycosylation, three-dimensional structure,
etc.). Our immunogens were derived from an M group consensus
sequence (MCON6), and they were produced in HEK 293 cells,
a human embryonic kidney cell line. In contrast, immunogens
evaluated by other groups were derived from a speciﬁc HIV-1
isolate: The OD1 construct reported by Yang et al. (2004), is based
on clade B YU2 strain and was produced in S2 Drosophila cells.
The construct studied by Chen et al. (2008, 2007) is based on a
clade C virus, CN54, and was produced in Sf9 Spodoptera frugiperda
cells using a recombinant baculovirus. In the study described by
Bhattacharyya et al. (2010), the immunogen was based on the
clade B HxBc2 strain and was produced in E. coli. The proteins
expressed in E. coli are non-glycosylated, and it is well known that
proteins expressed in mammalian and insect cells are glycosylated
differently (Marchal et al., 2001). These glycosylation variances can
have a signiﬁcant effect on the biochemical, structural, functional
and immunological properties of proteins. Additional studies will
be needed to determine full implication of differential glycosyla-
tion on the ability to induce nAbs against HIV-1.
Construction of envelope glycoproteins based on MCON6
sequence and their immunogenic properties were ﬁrst described
by Gao et al. (2005). In that study, soluble gp120 was produced from
293 T cells infected with a recombinant vaccinia virus. Four guinea
Fig. 7. Neutralizing activity of puriﬁed serum IgG. Serial dilutions of puriﬁed IgG from gp120, gp120-OD, and -OD3 immunized rabbits and negative control (PBS only)
were tested for neutralizing activity against the SF162.LS and MW965.26 viruses.
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pigs were immunized subcutaneously using RIBI-CWS (cell wall
skeleton from a tubercule bacillus) as an adjuvant. In these animals,
the average neutralization titer against SF162.LS was about 737, and
no neutralizing antibodies were detected against BAL. In our rabbits,
the average neutralization titers against the two viruses were 4089
and 144, respectively. Considering that the gp120 immunogen used
in the two studies are practically the same, and were produced in
the same cell line, the use of different adjuvants and/or the animal
model system used could be responsible for the different levels of
nAbs induced. It is also possible that antigenic dosage and immu-
nization schedule may also inﬂuence antibody titers.
The ID of gp120 is highly immunogenic, but the antibodies
induced against this domain are non-neutralizing. As such, we and
others have hypothesized that immunogens based solely on OD of
gp120 would be better at inducing bnAbs (e.g. VRC01) than the
intact gp120 because they would be able to focus the immune
response toward the OD. Although our immunogen/vaccine for-
mulation was able to induce fairly potent nAbs that other groups
failed to achieve in the past, they were not any better than what
could be induced with the intact gp120. In fact, the kinetics of
inducing nAbs were slower for gp120-OD than for gp120, requir-
ing more boosts. Interestingly, our gp120-OD3 was able to
induce higher nAb titers than gp120-OD. Not only that, it was
better able to induce nAb response more consistently than gp120
throughout the immunization study. It is not clear why nAb titers
decreased after the third or fourth immunization for gp120.
Although all three immunogens we evaluated were able to
neutralize multiple virus isolates from different clades, they were
limited to Tier 1 viruses. Based on V3 loop peptide inhibition data,
it is most likely that nAbs are targeting conserved elements on the
V3 loop. Presently, the structural parameters of the V3 loop on Tier
1 and Tier 2 viruses have not been clearly delineated. It is possible
that V3 loops on Tier 2 viruses are less exposed, thus avoiding
recognition by antibodies. In fact, recently determined crystal and
cryo-EM structures of a soluble gp140 trimer (SOSIP gp140) of a
Tier 2, clade A virus isolate (BG505) suggested that V3 loop could
be shielded by intra- and intertrimeric V1/V2 loops (Julien et al.,
2013; Lyumkis et al., 2013). At present, we do not know whether
the V3 loop on our MCON6 gp120 resembles those on Tier 1 or Tier
2 viruses. Regardless, better understanding of common structural
and immunogenic properties of the V3 loop on Tier 2 viruses
might allow better immunogen design that could induce bnAbs
against the V3 loop.
Based on the observation that V3 loop peptide was not able to
fully inhibit neutralizing activity of gp120-induced nAbs against
MW965.26, we hypothesize that some of the nAbs are targeting
non-V3 loop epitopes. Thus, enhancing immunogenicity of these
neutralizing epitopes and minimizing immunogenicity of the V3
loop could allow inducing higher titers of nAbs with greater
breadth. Perhaps combining our gp120 with other immunogens
that lack V3 loop (e.g. eOD-GT6) (Jardine et al., 2013) in a
heterologous prime-boost vaccine strategy could speciﬁcally
enhance antibody responses towards non-V3 neutralizing epi-
topes. To date, the immunogenicity of eOD-GT6 has not been
reported and will need to be evaluated before an effective prime-
boost strategy can be formulated.
In this study, we were able to determine only the linear immu-
nogenic epitopes. Identiﬁcation of non-linear epitopes would
better enhance our understanding of immunogenic properties of
gp120 and facilitate designing future immunogens. Unfortunately,
there is no simple, efﬁcient way to identify non-linear epitopes.
Development of a high throughput methodology capable of
identifying non-linear epitopes could allow for more thorough
characterization of B cell responses and facilitate AIDS vaccine
development.
Materials and methods
Construction of gp120, gp120-OD and -OD3
All of the constructs used in the study were derived from
pcDNA-MCON6gp160 (kindly provided by Dr. Beatrice Hahn (Gao
et al., 2005)). For a purpose unrelated to this study, MluI and
EcoRV restriction enzyme sites in the vector were eliminated ﬁrst
by mutating EcoRV (by digesting the plasmid with EcoRV and
XhoI, followed by Klenow ﬁll-in and ligation). The resulting
plasmid was digested with MluI followed by Klenow ﬁll-in and
ligation to eliminate the site. The resulting plasmid was renamed
pcDNAnMCON6gp160. A segment of DNA encoding gp160 was
cloned into pTM-NdeI (Cho et al., 1994) using EcoRI and BamHI.
Subsequently, a short DNA fragment between NdeI and EcoRI was
Fig. 8. Inhibition of neutralizing activity by V3 loop peptide. Neutralizing activity of puriﬁed IgG (50 mg/ml) from one rabbit from each immunogen group was evaluated in
the absence or the presence of various concentrations of MCON6 V3 peptide (TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH). VRC01 bnAb (5 mg/ml) that targets the CD4BS was
used as a negative control.
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removed by digesting with both enzymes followed by Klenow ﬁll-
in and ligation, to generate pTM-MCON6gp160. Restriction
enzyme sites (MluI and EcoRV) were inserted at the base of the
V3 loop by introducing silent mutations using site directed
mutagenesis. For the MluI site, sense primer 50-GAGATCAACTGC-
ACGCGTCCCAACAACAAC–30, and antisense primer 50-GTTGTTG-
TTGGGACGCGTGCAGTT-GATCTC–30 were used with QuikChanges
XL Site-Directed Mutagenesis Kit (Stratagene) according to man-
ufacturers protocol. EcoRV site was introduced using sense primer
50-CGAGATCATCGGC-GATATCCGCCAGGCCCAC–30 and antisense
primer 50-GTGGGCCTGGCGGATATCGCCGATGA-TCTCG–30. Under-
lined sequences signify restriction enzyme sites, and bold letters
represent mutagenesis sites. Restriction enzyme digestion and
DNA sequencing conﬁrmed correct cloning. The plasmid is
referred to as pTM-MCON6gp160-V3.
To clone gp120 with C-terminal 6His tag, gp120 coding
region was PCR ampliﬁed from pTM-MCON6gp160-V3 using sense
primer 50-GACCATCACCCTGCCCTGCC-30 and antisense primer
50-GGCCCCTCGAGTTAATGGTGATGATGGTGATGGCGCTTCTCGCGCT-
CCACCACGCG-30. The PCR fragment was digested with BsrG1 and
XhoI, and cloned into the corresponding sites in pTM-MCON-
6gp160-V3 to generate pTM-MCON6gp120-V3. Subsequently, the
BstEII2-HincII fragment from this construct was inserted into
BstEII-HindIII (after Klenow ﬁll-in) sites of pcDNAnMCON6gp160
to generate pcDNAnMCON6gp120.
The OD of gp120 was PCR ampliﬁed from 249STQLLL… to …
RPGGGD477 with forward primer 50-CCATGGTGACCGGATCCACC-
CAGCTGCTGCTGAACGGC-30 and reverse primer 50-GGCCT-CGA-
GAAGCTTAATGGTGATGATGGTGATGGTCGCCGCCGCCGGGGCG-30.
The ampliﬁed PCR fragment was then cloned into the BstEII and
HindIII sites of pcDNAnMCON6gp120 to form pcDNAnMCON6-
gp120-OD. To express gp120-OD3, three copies of OD were
covalently linked by a multistep process. First, an AgeI site was
introduced in pcDNAnMCON6gp120-OD at the C-terminal end by
site directed mutagenesis. The OD insert was prepared by BstEII
digestion, followed by Klenow ﬁll-in, and then HindIII digestion.
The pcDNAnMCON6gp120-OD vector backbone was prepared in a
similar manner, with an initial AgeI digestion, followed by blunt-
ing and HindIII digestion. The resulting fragments were ligated to
form pcDNAnMCON6gp120-OD2. Subsequently, the OD2 frag-
ment was removed with partial BstEII digestion, end blunting
and then HindIII digestion. The OD2 fragment was ligated into
the pcDNAnMCON6gp120-OD vector, as previously described,
to construct the ﬁnal pcDNAnMCON6gp120-OD3. Ultimately,
the OD3 contained three copies of OD covalently joined by a
four amino acid linker (STQL…GGGD-RVTG-STQL…GGGD-RVTG-
STQL…GGGD) encoded by 50-CGGGTGACCGGATCC-30 (BstEII and
BamHI sites are underlined; codons encoding RVTG are indicated
by boldface). All three proteins were fused to the original MCON-
6gp160 signal sequence, and all included a C-terminal 6His tag
to facilitate protein puriﬁcation.
Expression and puriﬁcation of gp120, gp120-OD and -OD 3
All three constructs were stably transfected into HEK 293 cells.
Cell culture supernatants containing the recombinant proteins
were collected for puriﬁcation using tandem afﬁnity chromato-
graphy as previously described (Wang et al., 2010) with few
modiﬁcations. First, recombinant proteins were enriched using
Con A Sepharose column (GE Healthcare Life Science). The proteins
were eluted from the column using elution buffer (20 mM Tris–
HCl, pH 7.4, 0.5 M NaCl, and 0.5 M methyl α-d-mannopyranoside).
The recombinant proteins were further puriﬁed using a Ni-NTA
column (Qiagen). After binding, column was washed with wash
buffer (20 mM Tris–HCl, pH 8.0, 0.5 M NaCl, and 5 mM imidazole).
Subsequently, the proteins were eluted using the same buffer
containing 250 mM imidazole. Remaining protein contaminants
were removed through a Q-Sepharose column (GE Healthcare Life
Science). The puriﬁed proteins, which were in the ﬂow-through
fraction, were concentrated with an Amicon Ultra concentrator
(Millipore) and stored at 80 1C. The protein purity was evaluated
by SDS-PAGE and silver staining.
Deglycosylation analyses of immunogens
2 mg of puriﬁed gp120, gp120-OD or -OD3 were deglycosy-
lated using either EndoH or PNGaseF (New England Biolabs) for
partial or complete deglycosylation, respectively. Proteins were
ﬁrst denatured in a denaturation buffer (5% SDS and 0.4 M DTT),
then incubated with 500 U of PNGaseF or EndoH for 3 h at 37 1C.
Proteins were subjected to SDS-PAGE using a Novex 4–20% Tris-
glycine Mini gel (Invitrogen), followed by Western blot analysis
with an anti-gp120 MCON6-speciﬁc mouse monoclonal antibody
(S7.5, hybridoma generated from gp120 immunized mouse, recog-
nizing gp120 outer domain, from unpublished work). Alexa Fluors
680 R-Phycoerythrin conjugated goat anti-mouse IgG (HþL) was
used as a secondary antibody. The blot was scanned with an
Odyssey infrared imager (Li-Cor)
Immunoprecipitation (IP) analyses
Puriﬁed gp120, gp120-OD or -OD3 were immunoprecipitated
with mAbs 17b (Kwong et al., 1998; Sullivan et al., 1998; Thali
et al., 1993; Trkola et al., 1996a; Wyatt et al., 1998, 1995), 2G12
(Buchacher et al., 1994; Crawford et al., 1999; Etemad-Moghadam
et al., 1999; Mascola et al., 1999; Trkola et al., 1996b), b12 (Barbas
et al., 1992; Burton et al., 1991, 1994; Roben et al., 1994), 447-52D
(Conley et al., 1994; Gorny et al., 1992, 1997, 1993; Nyambi et al.,
1998; Zolla-Pazner et al., 1995) NIH45–46 (Diskin et al., 2011),
VRC01 (X. Wu et al., 2010), PG9 and PG16 (Walker et al., 2009), all
of which were obtained through the NIH AIDS Research and
Reference Reagent Program (RRRP). MAb 3BNC60 heavy chain
and light chain variable regions were synthesized by Genscript
according to the published sequence (Scheid et al., 2011). The
synthesized heavy chain and light chain variable regions were
cloned into Ab expression vectors pFUSE-CHIg-hGI and pFUSE-
CLIg-hK (Invivogen), respectively. The 3BNC60 Ab was puriﬁed
from the supernatant of 293 F cells co-transfected with the
expression vectors using a protein A column (Pierce). IP was done
by incubating the proteins, mAbs and protein A-agarose in IP
buffer (10 mM Tris, pH 7.5, 200 mM NaCl, 1 mM EDTA, 0.5% Triton
X-100). After end-to-end rotation at 4 1C overnight, the bound
antigen–antibody complex was washed thrice with IP buffer.
Proteins were denatured and eluted from the resin by boiling for
5 min in 2 SDS-PAGE sample buffer. Immunoprecipitated pro-
teins were subjected to SDS-PAGE using a Novex 4–20% Tris-
glycine Mini gel (Invitrogen), followed by Western blot analysis
using mouse anti-gp120 outer domain mAb (S7.5, unpublished)
and goat anti-mouse IgG-HRP (Pierce). Protein bands were
detected by chemiluminescence on X-ray ﬁlms.
Surface plasmon resonance (SPR) analyses with IgG1 b12
IgG1 b12 was diluted in 10 mM glycine-HCl buffer (pH 3.0) to a
ﬁnal concentration of 10 μg/ml and then coated onto the CM5
sensor chip (Biacore) via carboxyl moieties on the dextran using
the standard primary amine coupling method until the resonance
signal reached 1300 resonance units (RUs). A reference surface was
prepared by activating and blocking a ﬂow cell in the absence of
b12. SPR analyses were performed with the Biacore 3000 (Biacore)
at room temperature in HBS-P running buffer (10 mM HEPES,
pH 7.4, 150 mM NaCl, and 0.005% (v/v) of the surfactant P20).
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To determine kinetic parameters for binding of immunogens
(gp120, gp120-OD and -OD3) to immobilized b12, sensorgrams
were obtained by passing various concentrations of analytes
(5–200 nM for gp120 and gp120-OD3; 10–500 nM for gp120-
OD) over the sensor surface at a ﬂow rate of 10 μL/min using a
2 min association phase and a 2 min dissociation phase. The speci-
ﬁc binding proﬁles of analytes to immobilized b12 were obtained
after subtraction of the response signal from the reference ﬂow
cell. Protein binding kinetics were evaluated using BiaEvaluation
(Biacore) based on 1:1 Langmuir binding model.
Preparation of zinc (Zn)-chitosan and immunization
Zn-chitosan was prepared as previously described (Seferian
and Martinez, 2000) with a few minor modiﬁcations. Brieﬂy, 2 g of
chitosan (Sigma, C3646) was dissolved in 100 ml of 2% acetic acid
followed by autoclave sterilization. The 2% (w/v) chitosan solution
was diluted 1:1 using deionized water, and 4 mL of the resulting
1% chitosan solution was added to 10 ml of 0.2 M zinc acetate. The
suspension was then mixed on an end-to-end rocker for 4 h at
room temperature (RT). The mixture was then sonicated using a
Branson Digital Soniﬁer for 5 min (70% Amplitude), and the pH
was adjusted to 12.0–12.5 with 10 N NaOH. The resulting pre-
cipitate was centrifuged at 1000 g for 10 min. The pellet was
washed twice with PBS (pH 7.4) by resuspension followed by
centrifugation at 1000 g for 10 min, and ﬁnally resuspended in
PBS (pH 8). Prior to immunization, antigens were loaded onto Zn-
chitosan by mixing the two (1:1000 w/w) for 3 h. Female New
Zealand white rabbits (2.5–3 kg; Charles River) were immunized
subcutaneously with 200 mg of protein with 200 mg of Zn-chitosan
in 1 ml (injected into 6–8 sites) on weeks 0, 3, 9, 15 and 27.
Three animals were immunized with each immunogen and two
animals were mock-immunized with Zn-chitosan in PBS. Blood
was collected from the central ear artery prior to (pre-immune)
and two weeks after each immunization and serum samples were
prepared. All of the studies conducted were approved by IACUC.
Enzyme-linked immunosorbent assay (ELISA)
Antigen-speciﬁc antibody levels were monitored by ELISA.
Puriﬁed immunogens were coated onto 96-well Nunc-Immuno
Plates overnight at 4 1C at 30 ng per well using an antigen coating
buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6).
Uncoated surface of the wells were blocked with 200 μl of a
blocking buffer (PBS, pH 7.4, containing 2.5% skim milk and 25%
Fetal Bovine Serum) for 1 h at 37 1C. Wells were subsequently
washed ﬁve times with a wash buffer (PBS containing 0.1% Tween
20) using a Biotek automated plate washer. Rabbit sera were
diluted in the blocking buffer (at indicated dilutions or 3-fold
serial dilutions for end-point titration), and 100 ml was added to
each well and incubated for 2 h at 37 1C. Wells were washed ﬁve
times, and further incubated for 1 h at 37 1C with a secondary
antibody (horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (HþL), Pierce; 1:3000 dilution in the blocking buffer).
Wells were washed again ﬁve times and HRP reaction was
initiated by adding 100 ml TMB HRP-substrate (Bio-Rad). The
reaction was stopped after 10 min by adding 50 ml of 2 N H2SO4.
Plates were read on a microplate reader (Versamax by Molecular
Devices) at 450 nm. All assays were done in duplicate. The end-
point ELISA titers were deﬁned as serum dilution factor that gave
readings of average 72 SD of the background (i.e. sera from
animals mock immunized with PBS).
The 15-mer overlapping peptide set for gp120 based on the M
group consensus sequence (CON-S) was obtained from the NIH
AIDS RRRP (Cat# 9487). V3, V4 and V5 peptides based on the
MCON6 sequence (H-TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQAH-
OH, H-MFNGTYMFNGTKDNSE-OH and H-GNNSNKNKTETFRPG-
OH, respectively) were synthesized commercially by CHI Scientiﬁc
(Maynard, MA). Peptides were coated onto wells at 20 pmol
per well.
Puriﬁcation of rabbit IgG
Rabbit IgG was puriﬁed from sera with Protein A column
(Pierce). Brieﬂy, 1 ml of rabbit serum was diluted 1:1 with Protein
A Binding buffer (Pierce) and then applied to a protein A column.
After washing, IgG was eluted with elution buffer (0.1 M glycine
pH 3.0), then was immediately adjusted to physiologic pH by
adding 100 ml of neutralization buffer (1 M Tris, pH 8.5) per 1 ml of
eluate. The eluted antibody was pooled and dialyzed in PBS. The
purity of puriﬁed IgG was conﬁrmed by SDS-PAGE. Antibodies
were kept at 80 1C.
Neutralization assay
Virus neutralization assays were done using the single cycle
HIV-1 pseudovirus infections of TZM-bl cells as previously
described (Li et al., 2005; Wei et al., 2002). Brieﬂy, heat inactivated
rabbit sera (56 1C for 1 h) or puriﬁed IgG were diluted in 100 ml of
Dulbecco's modiﬁed Eagle's medium supplemented with 10% heat
inactivated FBS (DMEM/FBS). Serum/antibody was mixed with 200
TCID50 (50% tissue culture infectious dose) of viruses in 50 ml and
incubated for 1 h at 37 1C. Into the mixture, 1104 TZM-bl cells in
DMEM/FBS containing DEAE-dextran (Sigma; 10 mg/ml ﬁnal con-
centration) were added. Plates were incubated at 37 1C for 48 h.
Cells were harvested and processed using Bright-Glo Luciferase
Assay kit (Promega) as per manufacturer's recommended protocol,
and luciferase activity was measured with Synerge 2 luminometer
(Biotek). The 50% inhibitory dose (ID50) or concentration (IC50) was
deﬁned as either the inverse of serum dilution or IgG concentra-
tion at which relative luminescence units (RLU) were reduced
by 50% compared to virus control wells after subtraction of
background RLU in cell-only control wells. For the protein/
peptide inhibition neutralizing assays, the same procedure was
followed except that antibodies were preincubated with gp120-OD
(50 mg/ml) or peptides (in varying concentrations) for 1 h at 37 1C.
Neutralization assays against a larger panel of pseudoviruses (in
TZM-bl and A3R5 cells) were assayed in Monteﬁori lab as pre-
viously described (Li et al., 2005; McLinden et al., 2013; Monteﬁori,
2005)
Statistical analyses
Statistical analyses were performed using SAS 9.3 and Graph-
Pad Prism 5. ELISA values were log-transformed and analyzed
using linear mixed models. Peptide, group, and their interaction
were used as ﬁxed effects, whereas animal and animal-peptide
interactions were random effects. Differences among groups were
assessed by F-tests followed by post-hoc Tukey's pairwise t-tests
for each group and region. P-values r0.05 were considered
signiﬁcant.
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